Independent Research Since 1997
Competitive Intelligence for Biopharma Decision-Makers
Proprietary reports, pipeline analysis, and custom research trusted by pharmaceutical professionals worldwide.
2025 Sales of Therapeutic Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and Therapeutic RNA
Comprehensive annual sales data for 400+ biologic drugs compiled from company disclosures. The definitive reference for biopharma commercial intelligence.
Multi-site licenses available
65+
Published reports
400+
Biologic drugs tracked
27yr
Independent analysis
95+
Companies covered
Featured Products
Our most referenced research and custom services
2025 Sales of Therapeutic Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and Therapeutic RNA
Pipeline of MUC16-Targeted Immunotherapeutics
Pipeline of CDH6-Targeted Immunotherapeutics
Pipeline of MUC1-Targeted Immunotherapeutics
Biopharma R&D Information & Custom Report Preparation
La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. We publish proprietary reports and prepare tailor-made custom reports on a fee-for-service basis.
Our products and subscription services are commercialized via our online store www.lamerie.com and via selected Resellers.
More InfoAt a Glance
65+ Reports
Published proprietary research
13 Categories
Therapeutic areas covered
7-Day Turnaround
For custom report delivery
Latest Products
Recently published and on-demand reports
2025 Sales of Therapeutic Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and Therapeutic RNA
Comprehensive 2025 sales data for 400+ biologic drugs.
Pipeline of MUC16-Targeted Immunotherapeutics
Complete competitive landscape of MUC16-targeted therapies in development.
Pipeline of CDH6-Targeted Immunotherapeutics
Pipeline analysis of CDH6-targeted immunotherapeutic approaches.
Pipeline of MUC1-Targeted Immunotherapeutics
Complete pipeline review of MUC1-targeted immunotherapy candidates.
Press Room
Industry insights and analysis
